The USP28/TFAP2A/MYC/SLC7A11 axis facilitates tumorigenesis by modulating ferroptosis and serves as a nanotherapeutic target in gemcitabine-resistant bladder cancer
Cancer Communications · 02.11.2026
DOI: 10.34133/cancomm.0071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Communications, online erschienen am 02.11.2026. Verfasst von Meiqi Xu und 12 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Xu, M., Wu, M., Pei, F., Pan, Z., Chen, K., Chen, X., Xu, S., Zhong, L., Wu, Z., Pan, X., Sun, B., Zhang, M., & Luo, Y. (2026). The USP28/TFAP2A/MYC/SLC7A11 axis facilitates tumorigenesis by modulating ferroptosis and serves as a nanotherapeutic target in gemcitabine-resistant bladder cancer. Cancer Communications. https://doi.org/10.34133/cancomm.0071
Vancouver
Xu M, Wu M, Pei F, Pan Z, Chen K, Chen X, et al. The USP28/TFAP2A/MYC/SLC7A11 axis facilitates tumorigenesis by modulating ferroptosis and serves as a nanotherapeutic target in gemcitabine-resistant bladder cancer. Cancer Communications. 2026. doi:10.34133/cancomm.0071
BibTeX
@article{Xu2026,
author = {Xu, Meiqi and Wu, Menyuan and Pei, Feng and Pan, Zhenming and Chen, Kailai and Chen, Xi and Xu, Shiyao and Zhong, Li and Wu, Zhichong and Pan, Xiang and Sun, Bin and Zhang, Manjie and Luo, Yakun},
title = {The USP28/TFAP2A/MYC/SLC7A11 axis facilitates tumorigenesis by modulating ferroptosis and serves as a nanotherapeutic target in gemcitabine-resistant bladder cancer},
journal = {Cancer Communications},
year = {2026},
doi = {10.34133/cancomm.0071}
}
EUVIMED